Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
<p>Clinical characteristics and their relationship with extending therapy after finishing 5-years adjuvant hormone therapy in women diagnosed with breast cancer in Stockholm, Sweden, 2005–2020.</p>
Wedi'i Gadw mewn:
| Prif Awdur: | Erwei Zeng (14958443) (author) |
|---|---|
| Awduron Eraill: | Wei He (14958446) (author), Arvid Sjölander (14958449) (author), Jenny Bergqvist (14958452) (author), Kamila Czene (14958455) (author) |
| Cyhoeddwyd: |
2025
|
| Pynciau: | |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Eitemau Tebyg
-
Figure 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
gan: Erwei Zeng (14958443)
Cyhoeddwyd: (2025) -
Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
gan: Erwei Zeng (14958443)
Cyhoeddwyd: (2025) -
Figure 3 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
gan: Erwei Zeng (14958443)
Cyhoeddwyd: (2025) -
Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
gan: Erwei Zeng (14958443)
Cyhoeddwyd: (2025) -
Figure 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia
gan: Alba L. Combita (22677298)
Cyhoeddwyd: (2025)